The present patent application relates a process for the production of compressed tablets using specific coated particles, wherein the coating (system) comprises at least one wax and/or at least one fat. Furthermore it relates to compressed (compacted) tablets and as well as to specific coated particles.

Described herein are compositions and methods for diagnosing late-onset Alzheimer's disease (LOAD), treating LOAD and assessing efficacy of therapeutic agents used to treat LOAD.

Described herein are compositions and methods for diagnosing late-onset Alzheimer's disease (LOAD), treating LOAD and assessing efficacy of therapeutic agents used to treat LOAD.

A trace element solution comprises at least the following metals zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide; manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate; copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate, and/or copper carbonate; selenium derived directly and/or indirectly from Na.sub.2SeO.sub.4 and/or Na.sub.2SeO.sub.3. The metals are present in a solution of water, chlorocresol and/or benzyl alcohol, at a concentration of metals of at least 95 mg/ml. The pH of the trace element solution adjusted by means of 30% NaOH in an injectable trace element solution that is visually stable.

A trace element solution comprises at least the following metals zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide; manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate; copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate, and/or copper carbonate; selenium derived directly and/or indirectly from Na.sub.2SeO.sub.4 and/or Na.sub.2SeO.sub.3. The metals are present in a solution of water, chlorocresol and/or benzyl alcohol, at a concentration of metals of at least 95 mg/ml. The pH of the trace element solution adjusted by means of 30% NaOH in an injectable trace element solution that is visually stable.

A trace element solution comprises at least the following metals zinc directly and/or indirectly from Zn-EDTA and/or Zn oxide; manganese directly and/or indirectly from Mn-EDTA and/or manganese carbonate; copper directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate, and/or copper carbonate; selenium derived directly and/or indirectly from Na.sub.2SeO.sub.4 and/or Na.sub.2SeO.sub.3. The metals are present in a solution of water, chlorocresol and/or benzyl alcohol, at a concentration of metals of at least 95 mg/ml. The pH of the trace element solution adjusted by means of 30% NaOH in an injectable trace element solution that is visually stable.

Provided are methods of sanitizing a subject, and methods of anesthetizing a subject. Further provided are methods of treating and/or preventing dermatological disorders, reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof. The methods may include administering to the subject an effective amount of a TRPA1 and/or TRPV4 inhibitor. Further provided are compositions including a TRPA1 and/or TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application.

Provided are methods of sanitizing a subject, and methods of anesthetizing a subject. Further provided are methods of treating and/or preventing dermatological disorders, reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof. The methods may include administering to the subject an effective amount of a TRPA1 and/or TRPV4 inhibitor. Further provided are compositions including a TRPA1 and/or TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application.

Provided are methods of sanitizing a subject, and methods of anesthetizing a subject. Further provided are methods of treating and/or preventing dermatological disorders, reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof. The methods may include administering to the subject an effective amount of a TRPA1 and/or TRPV4 inhibitor. Further provided are compositions including a TRPA1 and/or TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application.

Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.